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Abstract  
Background 
Protein tyrosine phosphatases (PTPs) like their antagonizing protein tyrosine kinases 
are key regulators of signal transduction thereby assuring normal control of cellular 
growth and differentiation. Increasing evidence suggests that mutations in PTP genes 
are associated with human malignancies. For example, mutational analysis of the 
tyrosine phosphatase (PTP) gene superfamily uncovered genetic alterations in about 
26 % of colorectal tumors. Since in these studies tumors have not been stratified 
according to genetic instability status we hypothesized that colorectal tumors 
characterized by high-level of microsatellite instability (MSI-H) might show an 
increased frequency of frameshift mutations in those PTP genes that harbor long 
mononucleotide repeats in their coding region (cMNR). 
Results 
Using bioinformatic analysis we identified 16 PTP candidate genes with long cMNRs 
that were examined for genetic alterations in 19 MSI-H colon cell lines, 54 MSI-H 
colorectal cancers, and 17 MSI-H colorectal adenomas. Frameshift mutations were 
identified only in 6 PTP genes, of which PTPN21 show the highest mutation 
frequency at all in MSI-H tumors (17 %). 
Conclusions 
Although about 32 % of MSI-H tumors showed at least one affected PTP gene, and 
cMNR mutation rates in PTPN21, PTPRS, and PTPN5 are higher than the mean 
mutation frequency of MNRs of the same length, mutations within PTP genes do not 
seem to play a common role in MSI tumorigenesis, since no cMNR mutation 
frequency reached statistical significance and therefore, failed prediction as a Positive 
Selective Target Gene. 
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Background  
Chromosomal instability (CIN) and aneuploidy are molecular features of most 
sporadic colorectal cancers (~85 %) and may confer a worse prognosis [1-3]. About 
15 % of colorectal cancers (CRC) show microsatellite instability (MSI) due to 
defective DNA mismatch repair (MMR; [4]). In hereditary non-polyposis colorectal 
cancer (HNPCC/ Lynch syndrome; about 5 % of all CRC cases) most of the tumors 
display this MSI phenotype [5]. As a common molecular theme, MMR-deficient MSI 
tumors of the colon and other organs accumulate numerous insertion/ deletion 
mutations [6,7] not only at non-coding but also at coding microsatellites (cMS) that 
cause translational frameshifts and abrogate normal protein function. Such frameshift 
protein derived neo-peptides can be highly immunogenic and are capable to induce 
cytotoxic T-cell-mediated killing of MSI-H tumor cells in vitro [8-11]. Frameshift 
mutations in cMS sequences of a large number of candidate genes have been 
identified [12-16] and mutations in some of them (TGFBR2, ACVR2, BAX; TCF-4) 
appear to provide a growth advantage to affected cells [17-20]. Both, sporadic and 
HNPCC-associated colorectal MSI-H cancers, show distinct clinico-pathological 
characteristics that include frequent proximal site, diploidy, poor differentiation, less 
distant metastases, peritumoral lymphocytic infiltrate, comparably good prognosis, 
and altered chemoresponsiveness [6,7,21-26]. Increasing evidence suggests that cMS 
mutations in a limited number of target genes appear to be selected for during MSI 
carcinogenesis and might account for some of these clinico-histopathological features. 
 
Protein tyrosine phosphatases (PTPs) like their antagonizing protein tyrosine kinases 
are key regulators of signal transduction thereby assuring normal control of cellular 
growth and differentiation [27]. Alterations in the delicate balance between tyrosine 
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phosphorylation and dephosphorylation contribute to the pathogenesis of different 
inherited or acquired human diseases including autoimmunity, diabetes, and 
cancer [27-29]. Several studies indicate that mutations in PTP genes may be involved 
in colorectal carcinogenesis. For example, increased PTPRA mRNA levels have been 
observed in late stage colorectal tumors [30] and frequent overexpression of the 
human transmembrane-type PTP SAP-1 may occur relatively late in the adenoma-
carcinoma sequence [31]. Expression profiling studies also suggested that PTPs 
appear to be involved in metastasis of colorectal cancer [32]. In a similar approach, 
differential expression of the human PTPN21 gene was observed when comparing 
MSI-H with microsatellite stable (MSS) colorectal cancer cell lines [33] and 
mutations in this gene were reported to occur in a subset of MSI-H colorectal 
carcinomas [34]. Additionally, a somatic mutation in the non-receptor PTP Shp2, 
encoded by the PTPN11 gene, has been detected in a single colon tumor with an 
increased frequency of somatic alterations, but without microsatellite instability [35]. 
Moreover, identification of the murine PTP gene Ptprj as a modifier locus conferring 
susceptibility to colorectal cancer also led to the detection of frequent deletions of the 
human PTPRJ gene in primary colon cancers [36]. Finally, systematic mutational 
analysis of the human PTP gene super family identified somatic mutations in six PTPs 
(PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26 % of colorectal 
cancers [37].  
 
However, whether coding mononucleotide repeats (cMNR) in PTP genes are specific 
targets of frameshift mutations in MMR-deficient colorectal tumors is still unknown. 
In the present study we identified 16 human PTP genes harboring coding region 
microsatellites and determined their mutation frequencies in MSI-H colorectal tumors. 
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About 32 % of MSI-H tumors showed frameshift mutations in any of these PTP 
genes. However, gene-specific cMNR mutation frequencies did not reach statistical 
significance according to our recently proposed model for Selective Target Gene 
prediction [16]. Hence, there is no significant statistical support for a common 
involvement of any of these PTP genes in MSI colon carcinogenesis. 
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Methods 
Cell Lines and Tumor Tissues 
Most of the cell lines analyzed in the present study have been described 
previously [15]. Additional human colorectal cancer cell lines were obtained from 
Cell Line Services (CLS), Heidelberg, Germany (Colo94H, Colo205, HCT8, 
SW1116, SW403, T84) or kindly provided by Dr. M. Brattain, University of Texas, 
Health Science Center, San Antonio, TX (CBS, FET), Dr. J. Wilson, Case Western 
Reserve University, Cleveland, Ohio (Vaco5, Vaco6, Vaco432, Vaco457), or Dr. I. 
Fidler (KM12). Cells were grown in RPMI supplemented with 10 % fetal calf serum 
(Life Technologies, Karlsruhe, Germany). Formalin-fixed and Paraffin-embedded 
tumor and matched normal mucosae samples were treated as described [38]. The MSI 
status of tumor cell lines (19 MSI-H, 17 MSS), primary colorectal tumors (54 MSI-H 
and matched normal mucosae), and colorectal adenomas (17 MSI-H, 6 MSS, and 
matched normal mucosae) has been determined using the NCI / ICG-HNPCC 
microsatellite marker panel [39] as previously described [38]. Whole blood DNA 
samples of 60 healthy donors served as additional MSS controls. Informed consent 
was obtained from all patients and blood donors.  
 
Candidate cMNR Sequences in PTP Genes 
Human PTP genes were sought in our cMNR database ([15] accessible at 
http://www.seltarbase.org, MNR_ensembl) that covers all human candidate coding 
mononucleotide repeats in the entire human genome annotated in the Ensembl 
database (Ensembl 19.34b, 2004). Candidate cMNRs with repeat length of at least 7 
repeat units were considered for further analysis.  
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cMNR Instability Analysis 
Primer design, DNA fragment and data analysis was performed as described [40]. 
Primer sequences and annealing temperatures are shown in Table 1 [see Additional 
file 1]. Frameshift mutations were verified by DNA sequence analysis.  
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Results 
cMNR instability of PTPs in MSI-H colorectal cancer cell lines 
A candidate set of 16 PTP genes that contained cMNR sequences composed of at least 
7 repeat units were retrieved from our cMNR database (Table 1 [see Additional file 
1], MNR_ensembl is accessible at http://www.seltarbase.org). Using DNA fragment 
analysis we examined cMNR length alterations of these candidate genes in 19 MSI-H 
and 17 MSS colorectal cancer cell lines. cMNR frameshift mutations occurred 
exclusively in MSI-H colorectal cancer cell lines and affected four PTP genes 
(Tables 2 and 4 [see Additional file 1]; PTPN21, PTPN13, PTPRS, PTPN23). Results 
of fragment analysis are exemplarily shown in figure 1. The highest mutation 
frequencies were associated with the A8 cMNRs in PTPN13 (22 %) and PTPN21 
(26 %). All mutations occurred in a heterozygous state and predominantly represented 
single nucleotide deletions (minus 1 allele, n = 10). Two were single nucleotide 
insertions (plus 1 allele, PTPN13 and PTPN21). No larger shifts could be detected. 
Overall, the larger fraction of MSI-H colorectal cancer cell lines (63 %; 12/19) 
showed frameshift mutations in any of the four affected PTP genes. 
PTP cMNR Mutations in MSI-H Primary Colorectal Carcinomas 
We next analyzed the same set of 16 PTP genes for cMNR frameshift mutations in 54 
MSI-H colorectal carcinomas and adjacent normal mucosa. Frameshift mutations in 
these primary tumors were identified in 6 PTP genes (PTPN21, PTPRS, PTPN5, 
PTPN23, PTPRA, PTPRE) comprising mutation targets shared by (PTPN21, PTPRS, 
PTPN23) or different from (PTPN5, PTPRA, PTPRE) those in the MSI-H cell 
lines (Tables 3 and 4 [see Additional file 1], Figure 1). In MSS mucosa samples such 
changes almost never occurred (1/703 analyses).Two genes, PTPN21 and PTPRS, 
were most frequently affected in primary colorectal tumors (16 % and 12 %, 
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respectively). However, primary tumors lacked frameshift mutations in the A8 repeat 
of PTPN13 and thus appeared to arise only in cultured MSI-H CRC cell lines. Since 
LS174T and LS180 are derived from the same primary tumor [41,42] and the overall 
mutation frequency is quite low it is very likely that this mutation already manifested 
within the primary tumor. Vice versa, mutations in three other PTPs (PTPN5, PTPRA, 
PTPRE) remained restricted to primary tumors and occurred at very low frequency 
(Tables 3 and 4 [see Additional file 1]). Overall, frameshift mutations in any of these 
6 PTP genes were observed in 32 % of MSI-H tumors. The most common type of 
mutation were single nucleotide deletions (16/21, 76 %) and all frameshift mutations 
appeared to affect only one allele (heterozygous). Interestingly, all PTP mutations are 
located within or upstream of the phosphatase domains and hence are expected to 
impair or completely abrogate phosphatase activity (Figure 2). 
PTPN21 cMNR Mutations in MSI-H Colorectal Adenomas 
Since mutations in the A8 coding repeat of PTPN21 were the most frequent genetic 
alterations shared by MSI-H cancer cell lines and primary tumors we also analyzed 
this coding repeat in 17 MSI-H and 6 MSS colorectal adenoma samples. As expected, 
no cMNR frameshift mutations were detected in the MSS adenomas. However, in 2 of 
17 MSI-H adenomas we identified deletion and insertion mutations (Table 4 [see 
Additional file 1], Figure 1). These results rather argue for an early event during MSI 
colorectal carcinogenesis. 
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Discussion  
The goal of this study was to determine type, frequency, and pattern of cMNR 
frameshift mutations in protein PTP genes in MSI-H colorectal cancer cell lines and 
primary colon tumors. This gene family was selected because PTPs are expected to 
exert tumor suppressive function and thus represent potential targets of inactivating 
mutations in DNA mismatch repair deficient tumors. Among the large number of PTP 
genes in the human genome we selected 16 PTP genes that contained coding region 
microsatellites of increased length (≥ 7 repetitive units). Our results provide evidence 
for frameshift mutations in six of these PTP genes (PTPN21, PTPRS, PTPN5, 
PTPN23, PTPRA, PTPRE) affecting about 32 % of MSI-H colorectal cancers. This 
frequency differs slightly from a previous study that reported PTP mutations in 26 % 
of unselected colorectal carcinomas [37]. Although most of the coding repeat-
harboring PTP genes (13/16 candidates) analyzed by us have also been examined by 
Wang and co-workers, different sets of mutated PTP genes were identified in both 
studies. In particular, we observed tumor-specific genetic alterations in PTPN21, 
PTPN23, PTPN5, PTPRA, PTPRE and PTPRS whereas mutations reported by Wang 
et al. were confined to PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, and PTPN14. This 
difference most probably can be explained by the different screening strategies used 
in these two studies. Wang et al. performed their initial mutational pre-screening on a 
set of 18 unselected colorectal tumors, This subset would be expected to include only 
2 to 3 MSI tumors based on a general MSI frequency of 15 % reported for unselected 
colorectal cancers .Since the type of mutation and the spectrum of affected genes is 
remarkably different among MSS and MSI-H tumors, the observed differences are not 
unexpected. However, there were also some consistent findings in both studies. For 
example, PTPN13 was examined by both groups but no cMNR mutations were 
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observed in a cumulative number of 69 MSI-H CRC samples ([43] and data presented 
here). Interestingly, Wang et al. described two nonsense or frameshift mutations at the 
expected MNR position within PTPN13. Unfortunately, any information about the 
MSI status of these tumors is missing. So, our investigation represent a reasonable 
completion of a systematic analysis of human PTP genes in human colorectal cancers. 
 
Recently, we proposed a statistical model that allows to predict positively or 
negatively selected target genes of MSI tumorigenesis in an organ-specific manner 
based on cMNR mutation frequencies [16]. According to the actual release of this 
model (www.seltarbase.org, release 200711), cMNRs of 7 or 8 repetitive units - in the 
absence of any biological selection pressure - are expected to show a mean somatic 
mutation rate of about 4 % and 9 % respectively. In order to qualify as positively 
selected MSI target genes, tumor-specific mutation frequencies for cMNRs of this 
length have to exceed 22 % and 28 %, respectively. The three most frequently 
mutated PTPs identified in the present study (PTPN21 [A8], PTPRS [C7], PTPN5 
[C7]) show mutation frequencies of 17 %, 12 %, and 6 %, respectively. The final 
overall mutation frequency of PTPN21 A8 (14.4 %) is even slightly lower, when 
considering data from the literature [14]. Certainly, we did not extend our mutation 
search to the entire coding sequence of each PTP gene, and therefore, additional 
mutations outside the cMNR sequence cannot be excluded. Furthermore, detailed 
studies of individual tumor types have provided compelling evidence that mutations 
of different genes but within the same pathway can have similar functional effects, i.e. 
leading to its disruption and providing a growth advantage to affected cells [37], as it 
has been proposed for apoptotic genes like Fas, Apaf-1, and Bcl-10 [44]. In 
conclusion, although these gene-specific mutation rates are higher than the mean 
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mutation frequencies for this length of repeats they do not reach statistical 
significance and prediction about positive Selective Target Genes in MSI-H 
tumorigenesis is not feasible. Therefore, human PTP genes do not seem to play a 
common role in MSI-H tumorigenesis. However, contribution to individual tumor 
development cannot be excluded. Furthermore, the observation of 2 mutations within 
a set of 17 MSI-H adenomas in PTPN21 argues for an early event in malignant 
transformation. 
 
Despite some structural diversity, the six PTP proteins found to be mutated in the 
present study share a catalytically active phosphatase that resides in one (PTPN21, 
PTPN23, PTPN5, PTPRS) or two (PTPRA) C-terminal domains [45]. Notably, all 
cMNR frameshift mutation sites are located upstream or within the first half of these 
catalytic domains (see Figure 2) resulting in truncated proteins that are expected to 
show partial or complete loss of phosphatase activity. However, all PTP frameshift 
mutations only affected a single allele leaving the cMNR on the remaining allele 
intact. The presence of contaminating normal inflammatory cells in these tumors may 
well account for this observation. Alternatively, the remaining wildtype copy may be 
silenced by epigenetic mechanisms. The absence of biallelic mutations in the analyzed 
tumors could be due to a dominant negative fashion or affection of gene 
dosage [46,47]. Shortened transcripts of murine PTPs lacking catalytic or interaction 
domains by alternative splicing can act in a dominant negative manner [48].  
 
From our analysis of preneoplastic lesions we further conclude that PTPN21 
frameshift mutations also occur in MSI-H colorectal adenomas albeit at lower 
frequency (12 %) thereby indicating an early step during MSI tumorigenesis. At the 
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protein level, PTPN21 is known to bind to and activate c-Src and Etk protein 
kinases [49,50]. Interestingly, activated Etk has been reported to trigger apoptosis in 
breast cancer cells via Stat1 and p21 [51]. By analogy, we hypothesize that 
inactivation of PTPN21 by cMNR frameshift mutations in MSI-H colon cancer cells 
might lead to Etk inactivation and subsequent inhibition of apoptosis. 
 
Conclusions  
The work presented here shows a systematic investigation using an evidence based 
approach: cMNRs of human PTP genes with the highest chance for mutational events 
in MSI-H colorectal tumors were selected. Although we observed a similar overall 
mutation frequency in MSI colorectal cancers compared to the results reported by 
Wang et al. for unselected colorectal cancers, a different set of PTP genes appears to 
be mutated in MSI tumors. Human PTP genes identified in the present study seem to 
play no common role in the tumorigenesis of MSI-H tumors, supported by statistical 
considerations. However, within individual MSI-H carcinogenesis such mutations 
could have had impact to malignant transformation, but so far no functional data exist 
that could confirm this hypothesis. 
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Figure legends 
Figure 1: Electropherograms of allelic shifts. 
Electropherograms of shifted alleles. DNA fragment analysis of a representative set of 
PTP cMNRs in a MSI-H colorectal tumor (KS2966A, Sam49) and MSI-H cancer cell 
lines (Co115, TC71, and HCT116). Corresponding wildtype alleles (wt, lower panel) 
are indicated together with tumor cell-specific allelic shifts marked by asterisks 
(upper panel). Allele intensities were determined (peak area) and ratios (f) of wildtype 
and novel alleles in primary tumors and cell lines were calculated, defining a 2-fold 
difference as threshold for allelic shifts. 
Figure 2: Domain structure of selected PTPs and sites of cMNR frameshift 
mutations. 
Structure of PTP proteins. Tyrosine phosphatase domains (PTPc) as well as frameshift 
mutation sites (arrowhead, stippled lines) are indicated. Remaining domain 
abbreviations: IG immunoglobulin like domain, FN fibronectin type 3 domain, KIND 
kinase non-catalytic C-lobe domain, ERM ezrin/radixin/moesin domain, PDZ Domain 
present in PSD-95, Dlg, and ZO-1/2., BRO1 BRO1-like domain, TM transmembrane 
domain. Despite PTPN5 is a non-receptor phosphatase there is a TM domain 
annotated within Ensembl. 
  - 20 - 
Tables 
Table 1: Coding microsatellites in candidate PTP genes examined in this study. 
For each of the 16 PTPs is given the official HUGO identification (hugoID), the 
actual Ensembl entry ID at http://www.ensembl.org/Homo_sapiens (ENSG), the 
chromosomal localization (Chr.), the former EMBL accession number (Acc.no.), the 
type of tract (nucleotide and length, cMNR), the exact position of the tract in relation 
to the sequence of the EMBL entry (Pos.), the annealing temperature for PCR (Ta) as 
well as the primer sequences (5’ -> 3’, sense and antisense) used for fragment analysis 
of the respective tract. 
Table 2: Allelic cMNR mutation status in MSI-H colorectal cancer cell lines. 
Wild type: wt; Deletions of one or two mononucleotides: –1, –2; Insertions of one or 
two mononucleotides: +1, +2; Analysis failed or not evaluable: 0. 
Table 3: Allelic cMNR mutation status in MSI-H colorectal carcinomas. 
For abbreviations see legend of Table 2. 
Table 4: PTP cMNR mutation frequencies in MSI-H colorectal cancer cell lines, 
tumors, and adenomas*. 
*Analysis restricted to PTPN21. 
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Additional files: 
 
Additional file 1 
File format: DOC 
Title: Supplemental material and results information 
Description: Table 1 shows the PTP candidate list including primer systems used for 
the fragment analysis, Tables 2 and 3 present cMNR mutation status 
information in MSI-H colorectal cancer cell lines and tumors, and Table 4 
summarizes the mutation frequencies of the PTP candidate genes in MSI-H 
colorectal cancer cell lines, tumors, and adenomas 
* *
*
*
*
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